GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inozyme Pharma Inc (NAS:INZY) » Definitions » FCF Yield %

Inozyme Pharma (Inozyme Pharma) FCF Yield % : -26.52 (As of May. 18, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inozyme Pharma FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Inozyme Pharma's Trailing 12-Month Free Cash Flow is $-77.59 Mil, and Market Cap is $284.54 Mil. Therefore, Inozyme Pharma's FCF Yield % for today is -26.52%.

The historical rank and industry rank for Inozyme Pharma's FCF Yield % or its related term are showing as below:

INZY' s FCF Yield % Range Over the Past 10 Years
Min: -39.78   Med: 0   Max: 0
Current: -26.52


INZY's FCF Yield % is ranked worse than
64.35% of 1557 companies
in the Biotechnology industry
Industry Median: -14.14 vs INZY: -26.52

Inozyme Pharma's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.


Inozyme Pharma FCF Yield % Historical Data

The historical data trend for Inozyme Pharma's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inozyme Pharma FCF Yield % Chart

Inozyme Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial - -7.57 -30.08 -137.15 -26.97

Inozyme Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.63 -24.09 -29.11 -28.26 -20.75

Competitive Comparison of Inozyme Pharma's FCF Yield %

For the Biotechnology subindustry, Inozyme Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inozyme Pharma's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inozyme Pharma's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Inozyme Pharma's FCF Yield % falls into.



Inozyme Pharma FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Inozyme Pharma's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-70.973 / 263.135088
=-26.97%

Inozyme Pharma's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-24.565 * 4 / 473.51439
=-20.75%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inozyme Pharma FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Inozyme Pharma FCF Yield % Related Terms

Thank you for viewing the detailed overview of Inozyme Pharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Inozyme Pharma (Inozyme Pharma) Business Description

Traded in Other Exchanges
N/A
Address
321 Summer Street, Suite 400, Boston, MA, USA, 02210
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
Executives
Robert Lorne Hopfner director, 10 percent owner C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Pivotal Bioventure Partners Fund I G.p., L.p. director 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I U.g.p. Ltd director 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I, L.p. director 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Matthew Winton officer: COO C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Sanjay Subramanian officer: SVP, CFO 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Henric Bjorn Bjarke officer: See Remarks ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Axel Bolte director, 10 percent owner, officer: See Remarks PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Inozyme Pharma, Inc. director 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Stephen J. Dipalma officer: Interim CFO C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Deborah Wenkert officer: SVP, CMO C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Scott D Sandell 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025